ELCC 2019 | TKIs to treat EGFRm-positive NSCLC

Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, discusses the current treatment options for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino compares the efficacy and toxicity of three known EGFR tyrosine kinase inhibitors (TKIs): gefitinib, dacomitinib, and osimertinib, in treating EGFRm-positive NSCLC.